INOVIO to Present at Jefferies 2022 Healthcare Conference

Rhea-AI Summary

INOVIO (NASDAQ: INO) announced that President and CEO Jacqueline Shea, along with Jeffrey Skolnik, SVP of Clinical Development for Oncology and HPV Therapeutics, will participate in a fireside chat and individual investor meetings at the Jefferies 2022 Healthcare Conference on June 8, 2022, at 1:00 PM EDT. A webcast of the presentation will be available on the INOVIO Investor Relations Events page. The company focuses on developing DNA medicines for infectious diseases, cancer, and HPV-associated diseases.

PLYMOUTH MEETING, Pa., May 23, 2022 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today announced that Jacqueline Shea, Ph.D., President and CEO, and Jeffrey Skolnik, M.D., SVP of Clinical Development for Oncology and HPV Therapeutics, are scheduled to participate in a fireside chat and 1x1 investor meetings at the Jefferies 2022 Healthcare Conference on Wednesday, June 8^th, 2022 at 1:00 PM EDT.

Jefferies 2022 Healthcare Conference
Date: Wednesday, June 8, 2022
Time: 1:00 PM EDT
Presentation Format: Fireside Chat

A webcast of the presentation will be available through the INOVIO Investor Relations Events page at https://ir.inovio.com/events-and-presentations/default.aspx. The presentation time is subject to change.

About INOVIO

INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and help treat people with cancer and HPV-associated diseases. Our DNA medicines are delivered using our proprietary smart device to produce a robust and tolerable immune response against targeted pathogens and cancers.

Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency/Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense/Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Richter-Helm BioLogics, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. For more information, visit www.inovio.com.

CONTACTS:

Media: Jeff Richardson, 267-440-4211, jrichardson@inovio.com
Investors: Ben Matone, 484-362-0076, ben.matone@inovio.com

 

View original content:https://www.prnewswire.com/news-releases/inovio-to-present-at-jefferies-2022-healthcare-conference-301552645.html

SOURCE INOVIO Pharmaceuticals, Inc.

FAQ

When is INOVIO's presentation at the Jefferies 2022 Healthcare Conference?

INOVIO's presentation is scheduled for June 8, 2022, at 1:00 PM EDT.

Who will represent INOVIO at the Jefferies 2022 Healthcare Conference?

Jacqueline Shea, President and CEO, and Jeffrey Skolnik, SVP of Clinical Development for Oncology and HPV Therapeutics, will represent INOVIO.

How can I watch INOVIO's presentation at the Jefferies Conference?

You can watch INOVIO's presentation via a webcast available on the INOVIO Investor Relations Events page.

What does INOVIO focus on in biotechnology?

INOVIO focuses on developing and commercializing DNA medicines to combat infectious diseases and treat cancer and HPV-associated diseases.

What is the significance of the Jefferies 2022 Healthcare Conference for INOVIO?

The Jefferies Conference provides INOVIO an opportunity to engage with investors and discuss their advancements in DNA medicine.